Effects of Bariatric Surgery and Lifestyle Changes on Fat and Liver Health
Official title: Change of Adipose Tissues and Triglyceride in Obese Patients With Non-alcoholic Fatty Liver Disease After Bariatric Surgery or Life-style Intervention
Run by Chinese University of Hong Kong · NCT03875625 · Data updated 2026-11-12
This study is testing how bariatric surgery and lifestyle changes affect fat and liver health in people with obesity and related metabolic issues.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | Chinese University of Hong Kong Academic / other |
| Locations | 1 site (Hong Kong, Shatin) |
| Status | Recruiting |
| Started | April 1, 2019 |
| Main results expected | December 31, 2025 |
| Study ends | June 30, 2026 |
| Registry record updated | February 13, 2025 |
| Trial ID | NCT03875625 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include individuals with a BMI of 25 or higher, particularly those with metabolic syndrome or morbid obesity.
✕Probably not a fit
Patients with other hepatic diseases or those on medications affecting liver fat may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to quantify changes in adipose tissues, liver triglycerides, and cholesterol levels following lifestyle interventions or bariatric surgery in patients with obesity and related metabolic disorders. It will investigate the role of brown adipose tissue as a potential biomarker for non-alcoholic fatty liver disease (NAFLD) and explore the relationship between brown fat, obesity, and NAFLD. The research will involve measuring various adipose tissue types and assessing liver inflammation and fibrosis through biopsies.
Why it matters
Potential benefit: If successful, this study could provide insights into effective treatments for obesity and NAFLD, potentially improving patient outcomes and quality of life.
How similar studies have gone: Previous studies have shown associations between obesity and NAFLD, but the specific role of brown adipose tissue as a biomarker is still being explored, making this approach novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * BMI ≥ 25-30 kg/m2 * BMI ≥ 30 kg/m2 with Metabolic syndrome * BMI ≥ 35 kg/m2 for morbid obesity Exclusion Criteria: * Other kind of hepatic diseases * Under medications known to affect liver fat * Waist circumference ≥ 150 cm * Weight ≥ 250 kg * MRI contraindications
Where it's running
-
The Chinese University of Hong Kong, Prince of Wale Hospital
Hong Kong, Shatin, Hong Kong Recruiting
Study contacts
- Principal investigator: Winnie C Chu, MD — Chinese University of Hong Kong
- Study coordinator: Winnie C Chu, MD
- Email: winniechu@cuhk.edu.hk
- Phone: (852) 3505 2299
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endoscopic sleeve gastroplasty for people with obesity and MASH
This study will test whether endoscopic sleeve gastroplasty plus lifestyle changes helps adults with obesity and MASH lose weight and improve liver health compared with lifestyle changes alone.
-
Understanding metabolic differences in patients with and without diabetes after a heart attack
This study looks at how heart attacks affect people with and without diabetes to see if there are differences that can help improve treatment and care.
-
Lowering insulin to reduce liver fat production
This study will try a short course of diazoxide to lower insulin and see if it reduces the liver's creation of new fat in adults with obesity, insulin resistance, and MASLD.
-
Linoleic acid–rich oil versus blended oil for adults with insulin resistance
This trial will test whether taking a linoleic acid–rich oil daily for 8 weeks improves insulin resistance in adults who already have insulin resistance.
-
Investigating insulin resistance using alpelisib in adults
This study is testing if a drug called alpelisib can help us understand how insulin works in healthy adults compared to those at risk for type 2 diabetes.
-
Timed-Restricted Eating for Improving Metabolic Health
This study is testing whether changing when people with obesity and insulin resistance eat can improve their metabolic health, liver fat, brain function, inflammation, and sleep quality.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.